Protagenic Therapeutics, Inc. - Common Stock (PTIX)
11.10
+8.07 (266.34%)
NASDAQ · Last Trade: May 19th, 11:13 PM EDT
Detailed Quote
Previous Close
3.030
Open
8.270
Bid
9.740
Ask
9.800
Day's Range
6.320 - 14.28
52 Week Range
0.1790 - 14.28
Volume
97,394,734
Market Cap
6.54M
PE Ratio (TTM)
-3.415
EPS (TTM)
-3.3
Dividend & Yield
N/A (N/A)
1 Month Average Volume
5,019,261
Chart
About Protagenic Therapeutics, Inc. - Common Stock (PTIX)
Protagenic Therapeutics Inc is a biotechnology company focused on the development of innovative therapies for neurological and psychiatric disorders. The company leverages its proprietary technologies to identify and develop peptides that target specific neuronal pathways, with the aim of addressing unmet medical needs in conditions such as depression and anxiety. Through its research and development efforts, Protagenic Therapeutics seeks to create effective treatment options that can enhance the quality of life for patients suffering from these complex disorders. Read More
Let's have a look at what is happening on the US markets after the closing bell on Monday. Below you can find the top gainers and losers in today's after hours session.
Protagenic Therapeutics shares soared 240% Monday on its all-stock merger with Phytanix Bio. New Phytanix targets CNS disorders with an expanded diverse pipeline and experienced team.
Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Protagenic Therapeutics, Inc. (NASDAQ: PTIX) and Phytanix Bio Inc. is fair to Protagenic shareholders. Upon completion of the proposed transaction, Protagenic shareholders are expected to own approximately 35% of the combined company.
BALA CYNWYD, Pa., May 19, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
NEW YORK, NY AND SANTA BARBARA, CA / ACCESS Newswire / May 19, 2025 / Protagenic Therapeutics, Inc. (Nasdaq:PTIX) (the "Company") and Phytanix Bio Inc. have entered into a definitive share exchange agreement pursuant to which the two entities will combine in an all-stock transaction (the "Combination"). The combined entity, to be called Phytanix, Inc., will bring together two pipelines focused on stress-related and CNS disorders, five preclinical assets and one clinical-stage asset.
As the regular session of the US market concludes on Tuesday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.
The US market is yet to commence its session on Tuesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
The regular session of the US market on Friday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.
